Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Imfinzi durvalumab Extensive-stage small cell lung cancer Reimburse with clinical criteria and/or conditions Complete
Imfinzi durvalumab Biliary tract cancer Reimburse with clinical criteria and/or conditions Complete
Imfinzi Durvalumab Unresectable Non-Small Cell Lung Cancer (NSCLC) Reimburse with clinical criteria and/or conditions Complete
Imfinzi durvalumab limited-stage small cell lung cancer (LS-SCLC) Pending
Imfinzi durvalumab resectable non-small cell lung cancer (NSCLC) Active
Imfinzi durvalumab, carboplatin, paclitaxel Endometrial cancer that is mismatch repair deficient (dMMR) Received
Imfinzi and Imjudo durvalumab and tremelimumab unresectable hepatocellular carcinoma Reimburse with clinical criteria and/or conditions Complete
Imfinzi, Imjudo durvalumab, tremelimumab Metastatic non-small cell lung cancer (NSCLC) Received
Imfinzi, Lynparza durvalumab, olaparib, carboplatin, paclitaxel Endometrial cancer that is mismatch repair proficient (pMMR) Received
Imvexxy estradiol Dyspareunia Reimburse with clinical criteria and/or conditions Complete